CA-QUOTIENT-SCIENCES
11.8.2020 14:02:03 CEST | Business Wire | Press release
ANA Therapeutics , a Silicon Valley-based biotech startup, and Quotient Sciences , a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005106/en/
Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to safely treat millions of people around the world.
“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski , COO, ANA Therapeutics. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”
Mark Egerton, Ph.D. , CEO of Quotient Sciences, said, “We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic. Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”
Under the scope of the agreement, ANA Therapeutics will access Quotient’s formulation and manufacturing expertise to develop and rapidly supply drug product for pivotal clinical trials in Q3 2020. The program will be conducted at Quotient’s facility in Garnet Valley, Pennsylvania.
About ANA Therapeutics
ANA Therapeutics is a Silicon Valley-based biotech startup working to develop niclosamide as a safe, widely accessible antiviral treatment for patients with COVID-19. A low-cost, scalable, and well-tolerated compound, niclosamide has the potential to be a needed treatment to help individuals who contract the novel coronavirus to beat it.
About Quotient Sciences
Quotient Sciences is an innovative global pharmaceutical development, clinical and commercial manufacturing organization providing services to the pharmaceutical and biotech industries. A combination of specialized skills and agile integrated processes enables Quotient Sciences to develop customized solutions which dramatically reduce the time and cost of getting drugs to market. Everything we do is driven by a deeply held belief, shared across the entire organization, that molecules need to become cures — fast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005106/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World6.8.2026 14:05:00 CEST | Press release
More than 4 million women have benefited through nonprofit organizations supported by the program since its launch. Mary Kay Inc., a global advocate for women’s empowerment, proudly reaffirms its commitment to enriching women’s lives worldwide through its signature Pink Changing Lives® Program – a multi-faceted global initiative that blends purpose-driven giving with cause-marketing to create meaningful, measurable impact across communities. Since 1996, the program has provided over $230 million in monetary and product donations to nonprofit organizations empowering women, transforming women’s health and safety, and protecting our natural resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806671194/en/ Mary Kay China supports the Hope for Pearl Program, providing financial assistance to girls from economically disadvantaged areas to receive a life-changing education, opening doors to new possibilities and bright fu
Perpetuals Reports 380% Hypothetical Return in Backtest of AI Engine Powering Risk-Free Trading Platform ‘UpsideOnly’6.8.2026 14:00:00 CEST | Press release
Results provide early evidence that BayesShield can identify potentially profitable trading signals by finding repeatable skill in trader activity375-day backtest using Perpetuals’s production code generated a hypothetical 380% non-compounded return, a period in which Bitcoin fell 40.2%The strategy achieved a return-to-drawdown ratio of 4.4, a measure comparing its overall return with the largest decline it experienced during the test Perpetuals.com Ltd (Nasdaq: PDC) today announced backtest results for version two of BayesShield, its patent-pending AI engine developed for UpsideOnly. UpsideOnly is a risk-free paper trading platform where users simulate trades using virtual money across global equity, commodity, foreign exchange and crypto markets. The platform is powered by BayesShield, an AI model that uses machine learning to identify consistently successful traders. It generates automated signals when enough qualified traders independently take the same position at approximately th
Adtran launches Mosaic One Fabric, empowering operators to build custom AI agents and workflows6.8.2026 14:00:00 CEST | Press release
News summary: Operators need the autonomy and tools to create AI agents and workflows that address their own business priorities Adtran’s Mosaic One Fabric enables operators to create, govern and scale AI agents without vendor lock-in Open foundation gives operators more control over their data, agents and token economics while accelerating innovation Adtran today launched Mosaic One Fabric, an expansion of its Mosaic One software platform, enabling operators to create AI agents and workflows around their own operational priorities. Rather than being limited to predefined agents, fixed use cases or vendor-controlled ecosystems, operators can build and scale AI on their own terms using the data, tokens and models that best fit their business, with the token economics visible and under their control. Mosaic One Fabric brings together trusted operational intelligence, vendor-agnostic AI integration and the guardrails needed to run AI safely across the network. By combining Adtran capabili
NetApp Acquires JetStream Software to Advance Cyber Resilience and Data Protection for the AI Era6.8.2026 14:00:00 CEST | Press release
Acquisition strengthens NetApp’s portfolio with recovery and mobility capabilities that help organizations reduce risk and accelerate transformation NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has acquired JetStream Software, a leader in VMware disaster recovery and migration. Enterprise customers continue to rely on VMware for many of their most critical applications. As organizations evaluate cloud adoption, they often seek ways to transition workloads while minimizing cost, complexity, and operational disruption. For many, disaster recovery serves as a practical first step, with production workloads migrating over time as cloud strategies mature. “Data has become the foundation for business growth, AI innovation, and operational continuity,” said George Kurian, Chief Executive Officer at NetApp. “As customers look to unlock greater value from their data while strengthening protection against disruption, bringing JetStream into NetApp expan
Omilia Secures $67 Million in Series B Funding to Accelerate Global Expansion of Its Agentic Self-Learning CX Platform for Large Enterprises6.8.2026 14:00:00 CEST | Press release
ARR surpasses $60 million, growth of more than 10x since the company's Series ANamed a Leader in The Forrester Wave™ Conversational AI Platforms for Customer Service, Q2 2026Investment led by transatlantic software & AI specialist Expedition Growth Capital Omilia, the Self-Learning Agentic CX company trusted by many of the world's largest enterprises, today announced a $67 million Series B funding round led by transatlantic software & AI specialist, Expedition Growth Capital. Omilia builds Agentic CX for the world's largest and most demanding enterprises – organizations often in regulated industries such as banking, insurance and healthcare, where security, scalability and cost predictability are non-negotiable. Its customers include Capital One, Discover, RBC, Taco Bell, DWP and PSEG. The company's voice-first AI platform, honed over more than 200 enterprise deployments, is built entirely on its own proprietary agentic Voice AI technology, and supports the most stringent enterprise se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom